Results 191 to 200 of about 80,856 (259)

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy, Andrea Glidden, Tracy Locke, Amy Scales, Elizabeth Gatewood, Jean‐Philippe Blanck, Jessica Castaneda‐Gill, Sharlin Patel, Yolanda D. Mahnke, Xuan Wang, Page Blas   +10 more
wiley   +1 more source

Conjugate Vaccines Targeting Tumor-Associated Carbohydrate Antigens. [PDF]

Vaccines (Basel)
Rosenglick N, Valentin G, Marineni K, Neto EP, Andreana PR.   +4 more
europepmc   +1 more source

Utility of blood‐based Mycobacterium tuberculosis antigen‐specific host biomarkers in differentiating between spinal tuberculosis and mechanical back pain: A proof‐of‐concept study

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Spinal tuberculosis (TB) is a severe form of musculoskeletal TB whose diagnosis remains challenging and may be misinterpreted as mechanical back pain. Mycobacterium tuberculosis antigen‐specific host blood protein biomarkers detectable in QuantiFERON supernatants may offer greater specificity to distinguish spinal TB from mechanical back pain, with ...
Bih H. Chendi, Leandre Van Rooyen, Theresa N. Mann, Johan H. Davis, Gerhard Walzl, Novel N. Chegou   +5 more
wiley   +1 more source

Comparison of Colorimetric (Enzyme-Linked Immunosorbent Assay (ELISA)) and Chemiluminescent Immunoassay (CLIA) Methods for Detection of Dengue Nonstructural Protein 1 (NS1) Antigen in Acute Dengue Infection. [PDF]

Cureus
Masood F, Nigar A, Tumrani R, Naqvi M, Awais Z, Heral HR, Masood A, Dar R, Shakoor M, Ansari F.   +9 more
europepmc   +1 more source

Humoral and cellular responses to SARS‐CoV‐2 variants after ancestral COVID‐19 vaccines in people with HIV and lung transplant recipients

Clinical &Translational Immunology, Volume 15, Issue 8, 2026.
This study compares the humoral and cellular immunogenicity of Dose 3 of Ancestral SARS‐CoV‐2 vaccine in participants with HIV and/or following lung transplantation with healthy controls. We highlight differences along a spectrum of immunocompromise, and the value of SARS‐CoV‐2 vaccination, even in the absence of detectable neutralisation responses ...
David WJ Griffin, Paul A Gill, Irene Boo, Shir Sun, Raffi Gugasyan, Alina Wang, Scott J Bornheimer, Stuart Turville, Anupriya Aggarwal, Greg I Snell, Glen P Westall, Emily SJ Edwards, Anna Coldham, Menno C van Zelm, Heidi E Drummer, James H McMahon   +15 more
wiley   +1 more source

Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer. [PDF]

J Immunother Cancer
Liu Y, Carter JM, Ma Y, Deshmukh SK, Sledge GW, Balko JM, Kachergus JM, Shi J, Gregory M, Gong J, Joensuu H, Perez EA, Stover D, Carey L, Sikov WM, Leon-Ferre R, Knutson KL, Boughey JC, Ingle JN, Kalari KR, Couch FJ, Asmann YW, Goetz MP, Thompson EA, Chumsri S.   +24 more
europepmc   +1 more source

Incorporation of Tn Antigen Mimetics into the MUC1

, 2023
Carmen Breton, Jesús Manuel Peregrina, Francisco Corzana, Paula Oroz, Ismael Compañon   +4 more
openaire   +2 more sources

Endogenous CD155 drives metabolic reprogramming via PI3K/AKT/HIF‐1α‐glycolysis axis to mediate anti‐PD‐1 resistance in non‐small cell lung cancer

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
CD155 is identified as a key driver of anti‐PD‐1 resistance in NSCLC. CD155 promotes tumour glycolysis and malignant progression via the PI3K/AKT/HIF‐1α signalling axis. AAV9_shCD155 combined with anti‐PD‐1 markedly inhibits tumour growth and promotes immune infiltration. Abstract Objective Anti‐PD‐1 therapy resistance remains a critical barrier in non‐
Wei‐Guang Du, Xi‐Yang Tang, Yu‐Long Zhou, Run‐Ze Zhang, Zhi‐Bo Feng, Meng‐Chao Li, Jun‐Yang Pan, Yao Lv, Xiao‐Liang Xu, Xiao‐Long Yan, Nan Ma, Jin‐Bo Zhao   +11 more
wiley   +1 more source

An in vitro approach for simulating divergent Golgi O-glycosylation of tumor-associated MUC1 from normal MUC1. [PDF]

Nat Commun
Nashed A, Dilsook K, Senapathi T, Naidoo KJ.   +3 more
europepmc   +1 more source